Shopping Cart
Remove All
Your shopping cart is currently empty
Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $290 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $755 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,200 | 2-4 weeks | 2-4 weeks |
| Description | Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1]. |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2415933-40-1 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.